Drugs / AZD1656
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials | ||||||
| Phase 1 | NCT01221545 | Oct 2010 → Jan 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01221519 | Sep 2010 → Jan 2011 | hyperglycemia, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01103622 | Jun → Dec 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01103609 | Apr → Aug 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01096940 | Mar → Aug 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01083212 | Mar → Jun 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01069926 | Mar → Oct 2010 | hypoglycemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01095991 | Mar → May 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01082120 | Feb → May 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00995787 | Oct 2009 → Feb 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00916604 | May → Oct 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00817271 | Feb → Apr 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00819884 | Jan → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00774553 | Oct 2008 → Jan 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00768105 | Sep 2008 → Mar 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00747175 | Aug 2008 → Apr 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00741689 | Aug → Dec 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00726427 | Jul → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04516759 | Aug 2020 → Apr 2021 | COVID-19 | St George Street Capital | Completed | No outcome recorded |
| Phase 2 | NCT05216172 | Dec 2019 → Sep 2022 | end stage renal failure, type 2 diabetes mellitus | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT01152385 | May 2010 → May 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01020123 | Oct 2009 → Feb 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00856908 | Feb → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00817778 | Jan → Jul 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00817505 Comparator | Dec 2008 → Mar 2009 | type 1 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00790153 Comparator | Nov 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01020123 ↗25 |
| Action | Activate | “activating glucokinase in both the pancreas and the liver” PMID 22943931 ↗ Nov 20121“Hexokinase type IV activator” CHEMBL3219124 ↗ |
| Modality | Small molecule | “The trial suggests a beneficial therapeutic effect of AZD1656 and identifies a new therapeutic concept: small molecule activation of endogenous homeostatic immune cells which...” PMID 35996565 ↗ Aug 2022 |
| Route | Oral | “single ascending oral doses of AZD1656” NCT00726427 ↗ |
| Target | GCK | “Hexokinase type IV activator” CHEMBL3219124 ↗ |